Literature DB >> 25456099

The effect of intensive glucose lowering therapy among major racial/ethnic groups in the Veterans Affairs Diabetes Trial.

Aramesh Saremi1, Dawn C Schwenke2, Gideon Bahn3, Ling Ge3, Nicholas Emanuele4, Peter D Reaven5.   

Abstract

OBJECTIVE: To examine the effect of intensive glycemic control on cardiovascular disease events (CVD) among the major race/ethnic groups in a post-hoc analysis of the VADT.
MATERIALS AND METHODS: Participants included 1111 non-Hispanic Whites, 307 Hispanics and 306 non-Hispanic Blacks randomized to intensive or standard glucose treatment in VADT. Multivariable Cox proportional hazards models were constructed to assess the effect of intensive glucose treatment on CVD events among race/ethnic groups.
RESULTS: Mean age was 60.4 years and median follow-up was 5.6 years. By design, modifiable risk factors were managed equally well in both treatment arms and only differed modestly between race/ethnic groups. HbA(1c) decreased significantly from baseline with intensive glucose treatment in each race/ethnic group, with a trend for a greater response in Hispanics (P=0.02 for overall comparison between groups). Intensive glucose treatment was associated with reduced risk of CVD events for Hispanics but not for others (hazard ratios ranged from 0.54 to 0.75 for Hispanics whereas they were consistently close to 1 for others). Sensitivity analyses with different definitions of race/ethnicity or limited to individuals free of previous known CVD yielded similar results.
CONCLUSIONS: The results of these analyses support the hypothesis that race/ethnicity is worthy of consideration when tailoring intensive treatment for individuals with long-standing type 2 diabetes. However, additional studies are needed to confirm the findings of this post-hoc analysis. Published by Elsevier Inc.

Entities:  

Keywords:  CVD; Ethnicity; Intensive glycemic control; Race; Type 2 diabetes

Mesh:

Substances:

Year:  2014        PMID: 25456099      PMCID: PMC4982373          DOI: 10.1016/j.metabol.2014.10.010

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  38 in total

Review 1.  Does aggressive glycemic control benefit macrovascular and microvascular disease in type 2 diabetes? Insights from ACCORD, ADVANCE, and VADT.

Authors:  Toni Terry; Kalyani Raravikar; Nalurporn Chokrungvaranon; Peter D Reaven
Journal:  Curr Cardiol Rep       Date:  2012-02       Impact factor: 2.931

2.  Comparison of frequency of coronary artery calcium in healthy Hispanic versus non-Hispanic white men by electron beam computed tomography.

Authors:  Peter D Reaven; Dewayne Thurmond; Alisa Domb; Richard Gerkin; Matthew J Budoff; Steven Goldman
Journal:  Am J Cardiol       Date:  2003-11-15       Impact factor: 2.778

Review 3.  Hispanic mortality paradox: a systematic review and meta-analysis of the longitudinal literature.

Authors:  John M Ruiz; Patrick Steffen; Timothy B Smith
Journal:  Am J Public Health       Date:  2013-01-17       Impact factor: 9.308

Review 4.  Intensive glycemic control and cardiovascular disease: are there patients who may benefit?

Authors:  Nalurporn Chokrungvaranon; James Deer; Peter D Reaven
Journal:  Postgrad Med       Date:  2011-11       Impact factor: 3.840

5.  Long-term effects of intensive glucose lowering on cardiovascular outcomes.

Authors:  Hertzel C Gerstein; Michael E Miller; Saul Genuth; Faramarz Ismail-Beigi; John B Buse; David C Goff; Jeffrey L Probstfield; William C Cushman; Henry N Ginsberg; J Thomas Bigger; Richard H Grimm; Robert P Byington; Yves D Rosenberg; William T Friedewald
Journal:  N Engl J Med       Date:  2011-03-03       Impact factor: 91.245

6.  Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes.

Authors:  Rena R Wing; Paula Bolin; Frederick L Brancati; George A Bray; Jeanne M Clark; Mace Coday; Richard S Crow; Jeffrey M Curtis; Caitlin M Egan; Mark A Espeland; Mary Evans; John P Foreyt; Siran Ghazarian; Edward W Gregg; Barbara Harrison; Helen P Hazuda; James O Hill; Edward S Horton; Van S Hubbard; John M Jakicic; Robert W Jeffery; Karen C Johnson; Steven E Kahn; Abbas E Kitabchi; William C Knowler; Cora E Lewis; Barbara J Maschak-Carey; Maria G Montez; Anne Murillo; David M Nathan; Jennifer Patricio; Anne Peters; Xavier Pi-Sunyer; Henry Pownall; David Reboussin; Judith G Regensteiner; Amy D Rickman; Donna H Ryan; Monika Safford; Thomas A Wadden; Lynne E Wagenknecht; Delia S West; David F Williamson; Susan Z Yanovski
Journal:  N Engl J Med       Date:  2013-06-24       Impact factor: 91.245

7.  Associations of SNPs in ADIPOQ and subclinical cardiovascular disease in the multi-ethnic study of atherosclerosis (MESA).

Authors:  Christina L Wassel; James S Pankow; Laura J Rasmussen-Torvik; Na Li; Kent D Taylor; Xiuqing Guo; Mark O Goodarzi; Walter R Palmas; Wendy S Post
Journal:  Obesity (Silver Spring)       Date:  2010-10-07       Impact factor: 5.002

8.  All-cause and cardiovascular mortality among diabetic participants in the San Antonio Heart Study: evidence against the "Hispanic Paradox".

Authors:  Kelly J Hunt; Ken Williams; Roy G Resendez; Helen P Hazuda; Steve M Haffner; Michael P Stern
Journal:  Diabetes Care       Date:  2002-09       Impact factor: 19.112

9.  Effect of a multifactorial intervention on mortality in type 2 diabetes.

Authors:  Peter Gaede; Henrik Lund-Andersen; Hans-Henrik Parving; Oluf Pedersen
Journal:  N Engl J Med       Date:  2008-02-07       Impact factor: 91.245

10.  Intensive glucose-lowering therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis.

Authors:  Peter D Reaven; Thomas E Moritz; Dawn C Schwenke; Robert J Anderson; Michael Criqui; Robert Detrano; Nicholas Emanuele; Moti Kayshap; Jennifer Marks; Sunder Mudaliar; R Harsha Rao; Jayendra H Shah; Steven Goldman; Domenic J Reda; Madeline McCarren; Carlos Abraira; William Duckworth
Journal:  Diabetes       Date:  2009-08-03       Impact factor: 9.461

View more
  5 in total

1.  The Risk of Coronary Heart Disease Associated With Glycosylated Hemoglobin of 6.5% or Greater Is Pronounced in the Haptoglobin 2-2 Genotype.

Authors:  Leah E Cahill; Majken K Jensen; Stephanie E Chiuve; Hadar Shalom; Jennifer K Pai; Alan J Flint; Kenneth J Mukamal; Kathryn M Rexrode; Andrew P Levy; Eric B Rimm
Journal:  J Am Coll Cardiol       Date:  2015-10-20       Impact factor: 24.094

Review 2.  Glucose targets for preventing diabetic kidney disease and its progression.

Authors:  Marinella Ruospo; Valeria M Saglimbene; Suetonia C Palmer; Salvatore De Cosmo; Antonio Pacilli; Olga Lamacchia; Mauro Cignarelli; Paola Fioretto; Mariacristina Vecchio; Jonathan C Craig; Giovanni Fm Strippoli
Journal:  Cochrane Database Syst Rev       Date:  2017-06-08

3.  A Clinical Conundrum: Intensifying Glycemic Control in the Presence of Advanced Diabetic Retinopathy.

Authors:  Eli Ipp; Monisha Kumar
Journal:  Diabetes Care       Date:  2021-09-21       Impact factor: 17.152

Review 4.  Epigenetic Changes in Endothelial Progenitors as a Possible Cellular Basis for Glycemic Memory in Diabetic Vascular Complications.

Authors:  Poojitha Rajasekar; Christina L O'Neill; Lydia Eeles; Alan W Stitt; Reinhold J Medina
Journal:  J Diabetes Res       Date:  2015-05-28       Impact factor: 4.011

Review 5.  Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine.

Authors:  Gaia Chiara Mannino; Francesco Andreozzi; Giorgio Sesti
Journal:  Diabetes Metab Res Rev       Date:  2019-01-07       Impact factor: 4.876

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.